PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.38
+0.08 (+1.51%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.30
Open5.28
Bid5.10 x 29200
Ask5.43 x 4000
Day's Range5.22 - 5.47
52 Week Range4.68 - 9.42
Volume1,358,369
Avg. Volume1,441,248
Market Cap454.839M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of PGNX earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Progenics Pharmaceuticals Inc Earnings Call

  • Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks10 days ago

    Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    Progenics: 3Q Earnings Snapshot

    The New York-based company said it had a loss of 30 cents per share. Losses, adjusted for one-time gains and costs, were 9 cents per share. The biopharmaceutical company posted revenue of $5.3 million ...

  • Benzingalast month

    The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

    Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zackslast month

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • Benzingalast month

    Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results'

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) shares were rallying Friday morning in response to positive trial data for a prostate cancer imaging agent.  What Happened The company announced  results ...

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist2 months ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • Simply Wall St.2 months ago

    Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 32.98% Discount

    I am going to run you through how I calculated the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) by estimating the company’s future cash flows and discounting them to their Read More...

  • Progenics Pharma's Stock Down on Dismal Phase III Study Data
    Zacks2 months ago

    Progenics Pharma's Stock Down on Dismal Phase III Study Data

    Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.

  • Associated Press2 months ago

    Qualcomm and Tailored Brands rise; Kroger stumbles

    Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...

  • Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today
    Motley Fool2 months ago

    Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today

    A phase 3 trial failed, but all isn't lost for the biotech.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • CNBC2 months ago

    After-hours buzz: PVTL, PGNX & more

    Check out the companies making headlines after the bell: Pivotal Software PVTL shares tumbled more than 20 percent in after-hours trading despite reporting second-quarter earnings numbers that beat on both the top and bottom line.

  • MarketWatch2 months ago

    Progenics stock falls on missed study endpoint

    Progenics Pharmaceuticals Inc. shares fell in the extended session Wednesday after the cancer drug company said one of its imaging agents was not sensitive enough to detect prostate cancer in a clinical study. Progenics shares fell 19% after hours, following a 1.6% decline to close the regular session at $7.30. The company said a late-stage clinical trial found its so-called "1404" imaging agent needed to positively detect prostate cancer with a 60% or more sensitivity but did so with a 47% to 51% range. The imaging agent, however, was able to detect the absence of prostate cancer correctly with a specificity of 71% to 75% compared with the study target of 60% or more.

  • Amicus Therapeutics: Recent Developments, Financial Overview
    Market Realist2 months ago

    Amicus Therapeutics: Recent Developments, Financial Overview

    In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.

  • How Analysts View Amicus Therapeutics in September
    Market Realist2 months ago

    How Analysts View Amicus Therapeutics in September

    On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.

  • Analysts Are Bullish on Verastem in September
    Market Realist2 months ago

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • Why Invitae Stock Rose 23% in Week Ended August 24
    Market Realist3 months ago

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist3 months ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist3 months ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist3 months ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist3 months ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • Benzinga4 months ago

    Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...

  • Associated Press4 months ago

    Progenics: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 20 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. Progenics shares have risen 34 percent since ...